Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus paracasei GMNL-143
- Development stage
- Unknown
- Lead developer
- GenMont Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
Lactobacillus paracasei GMNL-143 is a proprietary strain of the lactic acid bacterium Lactobacillus (Lacticaseibacillus) paracasei developed by GenMont Biotech as a probiotic/para-probiotic for oral health applications. It is a gram-positive, non-spore-forming, non-motile, facultative anaerobic rod with a growth temperature range of 25–45°C and pH tolerance from 4.0 to 10.0.[1] Genomic analysis of GMNL-143 has identified multiple bacteriocin genes and the absence of transferable antibiotic resistance or virulence genes, supporting a favorable safety profile.[2] In preclinical and clinical studies, heat-killed GMNL-143 formulated in toothpaste demonstrates strong coaggregation with key oral pathogens (including Streptococcus mutans, Porphyromonas gingivalis, Fusobacterium nucleatum, and Prevotella intermedia), inhibition of pathogen adhesion to gingival epithelial cells, and suppression of growth of some anaerobic pathogens, collectively shifting oral microbiota toward a healthier state and improving gingival index in adults with mild to moderate gingivitis.[2][3][4]
- Brand names
- GMNL-143 toothpasteGMNL143 toothpasteGMNL 143 toothpaste
- Other names
- Lacticaseibacillus paracasei GMNL-143L. paracasei GMNL-143
Beyond the preview
Go deeper on Lactobacillus paracasei GMNL-143.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus paracasei GMNL-143.